Safety of LEO 43204 0.018%, 0.037% and 0.1% for Actinic Keratosis Applied Once Daily for Three Consecutive Days on Face/Chest, Scalp and Trunk/Extremities, Respectively

Trial Profile

Safety of LEO 43204 0.018%, 0.037% and 0.1% for Actinic Keratosis Applied Once Daily for Three Consecutive Days on Face/Chest, Scalp and Trunk/Extremities, Respectively

Completed
Phase of Trial: Phase II

Latest Information Update: 05 May 2017

At a glance

  • Drugs Ingenol disoxate (Primary)
  • Indications Actinic keratosis
  • Focus Adverse reactions
  • Sponsors LEO Pharma
  • Most Recent Events

    • 24 Nov 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 10 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov
    • 02 Feb 2015 Planned initiation date changed from 1 Jan 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top